glp 1 comorbidities Paving the way for expanded GLP-1 coverage | Insights & Events The expanding landscape of GLP-1

CDC (updated 21 Jun 2018)

These mechanisms collectively reduce appetite and promote weight loss, making it an effective option for individuals struggling with metabolic conditions

Summary: GLP-1 receptor agonists are not licensed for anxiety treatment and lack established evidence for direct anxiolytic effects, though some patients may experience secondary psychological improvements through metabolic health gains

Georgala S, Schulpis KH, Georgala C, Michas T

Some patch ingredients (berberine, green tea catechins) have shown modest GLP-1 signaling effects in animal models with oral dosing at gram-level quantities

After the first consultation and baseline labs, we work together to create a plan, keep an eye on your progress, and change the plan based on objectives and how you feel